Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (ATXS)
NASDAQ:ATXS
ATXS Stock Chart & Stats
$12.82
-$0.31(-3.58%)
At close: 4:00 PM EST
$12.82
-$0.31(-3.58%)
Day’s Range― - ―
52-Week Range$3.56 - $13.29
Previous CloseN/A
Volume35.54K
Average Volume (3M)1.09M
Market Cap
$731.83M
Enterprise Value$294.35M
Total Cash (Recent Filing)$227.72M
Total Debt (Recent Filing)$4.46M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 05, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding57,084,840
10 Day Avg. Volume314,228
30 Day Avg. Volume1,091,585
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-6.16
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue416.92
Enterprise Value/Gross Profit416.92
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$13.00Price Target Upside1.40% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition And Market ExpansionBioCryst Pharmaceuticals is acquiring Astria in a cash/stock deal, representing an implied ATXS per share value of $13.00, equating to ~$700M in enterprise value.
Innovative Therapy DevelopmentNavenibart is positioned as a potential first-choice preventative treatment in HAE, with an efficacy profile that could exceed competitors.
Strategic PartnershipsAstria's partnership with Kaken Pharmaceutical represents a strategic opportunity to broaden navenibart’s market reach and validate its potential as a first-in-class HAE therapy option.
Bears Say
Financial PerformanceThe net loss for Q3 2025 was $31.6M ($0.55/share), indicating a higher loss compared to Q3 2024.
Stock Rating AdjustmentBased on Astria's current share price versus the acquisition price, the rating is moved to Market Perform.
Strategic RealignmentBioCryst intends to seek strategic alternatives for STAR-0310 due to it not fitting within their rare disease strategy.
Astria Therapeutics News
ATXS FAQ
What was Astria Therapeutics’s price range in the past 12 months?
Astria Therapeutics lowest stock price was $3.56 and its highest was $13.29 in the past 12 months.
What is Astria Therapeutics’s market cap?
Astria Therapeutics’s market cap is $731.83M.
When is Astria Therapeutics’s upcoming earnings report date?
Astria Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 57 days.
How were Astria Therapeutics’s earnings last quarter?
Astria Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.159.
Is Astria Therapeutics overvalued?
According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued.
Does Astria Therapeutics pay dividends?
Astria Therapeutics does not currently pay dividends.
What is Astria Therapeutics’s EPS estimate?
Astria Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Astria Therapeutics have?
Astria Therapeutics has 57,084,840 shares outstanding.
What happened to Astria Therapeutics’s price movement after its last earnings report?
Astria Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 0.32%.
Which hedge fund is a major shareholder of Astria Therapeutics?
Currently, no hedge funds are holding shares in ATXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Astria Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.00 (1.40% Upside)
$13.00 (1.40% Upside)
Blogger Sentiment
Bullish
ATXS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 24.3%
Last 30 Days ▼ 24.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.70%
12-Months-Change
Fundamentals
Return on Equity
-43.15%
Trailing 12-Months
Asset Growth
-24.82%
Trailing 12-Months
Company Description
Astria Therapeutics
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
ATXS Stock 12 Month Forecast
Average Price Target
$13.00
▲(1.40% Upside)
Technical Analysis
Autolus Therapeutics
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
PureTech Health
―
Monte Rosa Therapeutics
―
Ownership Overview
Currently, No data available
---